Sinopharm Group CoSHTDF -2.67%78 Gross Margin % is 7.38% as of Dec. 2025, which is 12% below its 10-year median of 8.35. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $3.03 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 118 Medical Distribution companies, Sinopharm Group Co ranks worse than 87.29% on this metric.
Sinopharm Group Co Ltd gross margin has been in long-term decline. The average rate of decline per year is -3.8%.
The historical rank and industry rank for Sinopharm Group Co's Gross Margin % or its related term are showing as below:
SHTDF'
s Gross Margin % Range Over the Past 10 Years
Min: 7.25 Med: 8.35 Max: 9.06
Current: 7.25
During the past 13 years, the highestGross Margin % of Sinopharm Group Co was 9.06%. The lowest was 7.25%. And the median was 8.35%.
SHTDF's Gross Margin % is ranked worse than 87.29% of 118
companies
in the Medical Distribution industry
Industry Median: 14.975
vs SHTDF: 7.25
Sinopharm Group Co had a gross margin of 7.38% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Sinopharm Group Co was -3.80% per year.
Sinopharm Group Co (OTCPK:SHTDF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Sinopharm Group Co had a gross margin of 7.38% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Sinopharm Group Co Gross Margin % Related Terms
Sinopharm Group Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sinopharm Group Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co Gross Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Sinopharm Group Co (SHTDF) has a Gross Margin % of 7.38% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Sinopharm Group Co and its competitors. This is 12% below median its historical median of 8.35. Over the past decade, Sinopharm Group Co's Gross Margin % has ranged from 7.25 to 9.06. According to the industry distribution chart, Sinopharm Group Co ranks #103 out of 118 companies in the Medical Distribution industry, placing it in the top 87.3%.
Is Sinopharm Group Co's Gross Margin % too high?
Sinopharm Group Co's current Gross Margin % of 7.38% is 12% below median its 10-year median of 8.35. Over the past 10 years, this metric has ranged from a low of 7.25 to a high of 9.06. The Medical Distribution industry median Gross Margin % is 14.98. Sinopharm Group Co's value of 7.38% is 50.7% below this industry median. Based on the distribution chart, Sinopharm Group Co ranks #103 out of 118 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's Gross Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #103 out of 118 companies for Gross Margin %. This places Sinopharm Group Co in the lower half of its industry. The industry median Gross Margin % is 14.98. Sinopharm Group Co's value of 7.38% is 50.7% below this benchmark. Historically, Sinopharm Group Co's own Gross Margin % has ranged from 7.25 to 9.06 over the past decade. While the company's 10-year median is 8.35 vs. the industry median of 14.98, Sinopharm Group Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Distribution company?
The median Gross Margin % among Medical Distribution companies is 14.98, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current Gross Margin % of 7.38% is 50.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median Gross Margin % is 14.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current Gross Margin % is 7.38%, which is 12% below median its own 10-year median of 8.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.03, compared to a current price of $2.29 — trading 24.5% below its estimated fair value. The current Gross Margin % is 7.38%, which is 12% below median its 10-year median of 8.35 and 50.7% below the Medical Distribution industry median of 14.98. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current Gross Margin % is 7.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.29 is trading 24.5% below its estimated GF Value™ of $3.03.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
Gross Margin %: 7.38% (12% below median its 10-year median of 8.35)
GF Value™: $3.03 vs. price of $2.29 (24.5% below fair value)
Industry Position: 50.7% below the Medical Distribution median (#103 of 118)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
